A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer
This study is testing a combination of two medications to see how well they work against solid tumors that struggle to repair their own DNA. Researchers are investigating if these drugs can effectively slow down or shrink these types of cancers when other treatments haven't worked.
This trial is for adults over 18 with advanced or recurring solid tumors that show specific genetic changes related to DNA repair. You must be active, healthy enough for daily activities, and not currently participating in other medical research trials.
Participants will receive a combination of two different drugs designed to target the cancer's DNA repair process. You will be monitored closely by the medical team to see how your body responds to the treatment and to ensure your safety.
This study is taking place in Germantown, Tennessee, and the current recruitment status is currently unknown.
- 1Tests a two-drug combination therapy for specific types of solid tumors.
- 2Requires a genetic test to confirm the presence of DNA repair defects.
- 3Participants must be generally healthy and able to perform normal daily activities.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.